Sign in
Latest News
Pharmaceuticals
BioPharma
MedTech
B2B News
Healthcare
Health Insurance
Nutrition & Wellness
Agro-Pharma
Animal Health
Reviews
Regulations
Product Reviews
Service Reviews
About Us
Sign in
Welcome!
Log into your account
your username
your password
Forgot your password?
Password recovery
Recover your password
your email
Search
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Password recovery
Recover your password
your email
A password will be e-mailed to you.
Sunday, September 8, 2024
Sign in / Join
Latest News
Pharmaceuticals
BioPharma
MedTech
B2B News
Healthcare
Health Insurance
Nutrition & Wellness
Agro-Pharma
Animal Health
Reviews
Regulations
Product Reviews
Service Reviews
About Us
Facebook
Instagram
Twitter
Vimeo
Youtube
Latest News
Pharmaceuticals
BioPharma
MedTech
B2B News
Healthcare
Health Insurance
Nutrition & Wellness
Agro-Pharma
Animal Health
Reviews
Regulations
Product Reviews
Service Reviews
About Us
Search
Home
Authors
Posts by Alex Hoffmann
Alex Hoffmann
17 POSTS
0 COMMENTS
http://propharmanews.com
How J&J Is Embracing Quantum Computing
Alex Hoffmann
-
July 1, 2024
0
Eli Lilly’s UK Investment Concerns
Alex Hoffmann
-
July 1, 2024
0
Moderna’s Covid-Flu Combo Vaccine
Alex Hoffmann
-
July 1, 2024
0
Sanofi’s $1.6bn German Investment Strategy
Alex Hoffmann
-
July 1, 2024
0
Pfizer’s Hazardous Waste Lawsuit
Alex Hoffmann
-
June 28, 2024
0
Analyzing Moderna Stock Collapse
Alex Hoffmann
-
June 28, 2024
0
AbbVie Announces Acquisition of Celsius Therapeutics
Alex Hoffmann
-
June 27, 2024
0
Merck’s Capvaxive Vs. Pfizer’s Prevnar
Alex Hoffmann
-
June 27, 2024
0
Five US States Sue Pfizer Over COVID-19 Vaccine Safety
Alex Hoffmann
-
June 26, 2024
0
Why Eli Lilly Partnered with OpenAI
Alex Hoffmann
-
June 26, 2024
0
1
2
Page 1 of 2
TOP AUTHORS
Alex Hoffmann
17 POSTS
0 COMMENTS
http://propharmanews.com
propharmanews
146 POSTS
0 COMMENTS
https://propharmanews.com
Most Read
Regulatory Update — Week of Sept. 2, 2024
September 7, 2024
Judge orders J&J to pay Auris investors more than $1B for merger violations
September 7, 2024
Cloud moment – PharmaTimes
September 6, 2024
European Commission grants orphan drug designation for Vivet’s VTX-806
September 6, 2024